Previous Close | 2.9300 |
Open | 2.8750 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 2.8450 - 2.9200 |
52 Week Range | 2.7300 - 7.8700 |
Volume | |
Avg. Volume | 19,111 |
Market Cap | 19.323M |
Beta (5Y Monthly) | 0.68 |
PE Ratio (TTM) | 0.74 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Nov 16, 2023 |
1y Target Est | N/A |
SAN DIEGO, May 09, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.
SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additionall
SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer ("mCRC") in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation ("OXPHOS"), in combination with bevacizumab (Avastin®) had